Kobayashi Pharmaceuticals
Kobayashi Pharmaceuticals Co., Ltd., commonly known as Kobayashi, is a leading player in the pharmaceutical and consumer healthcare industry, headquartered in Japan. Established in 1907, the company has a rich history marked by innovation and growth, with significant operations across Asia and beyond. Kobayashi is renowned for its diverse range of products, including over-the-counter medications, personal care items, and health supplements. Their unique formulations and commitment to quality set them apart in a competitive market. With a strong focus on research and development, Kobayashi has achieved notable milestones, solidifying its position as a trusted name in healthcare. The company continues to excel, leveraging its expertise to meet the evolving needs of consumers, while maintaining a reputation for excellence in product efficacy and safety.
DitchCarbon Score
How does Kobayashi Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kobayashi Pharmaceuticals's score of 17 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kobayashi Pharmaceuticals's reported carbon emissions
In 2022, Kobayashi Pharmaceuticals reported total greenhouse gas emissions of approximately 6000000 kg CO2e for Scope 1 and about 18000000 kg CO2e for Scope 2, with significant Scope 3 emissions reaching approximately 551000000 kg CO2e. This indicates a substantial reliance on indirect emissions, particularly from purchased goods and services. Kobayashi Pharmaceuticals has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 51% by 2030, using 2018 as the base year. Additionally, the company targets a 15% reduction in absolute Scope 3 emissions within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to global efforts to limit temperature rise to 1.5°C. The company's emissions data reflects a proactive approach to addressing climate change, with a clear focus on both direct and indirect emissions reduction strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 6,635,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 23,036,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 00,000,000 | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kobayashi Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
